{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:14:15Z","timestamp":1794680055674,"version":"4.9.1"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific Research Seed Fund of Peking University First Hospital","award":["2025SF053"],"award-info":[{"award-number":["2025SF053"]}]},{"name":"the University of Wisconsin \u2013 Madison and the National Institutes of Health","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04338-w","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:29:10Z","timestamp":1775568550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nanomedicine in immunotherapy of urinary system tumors: advances, synergistic strategies, and translational challenges"],"prefix":"10.1186","volume":"24","author":[{"given":"Wenpeng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaonan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia S.","family":"Reuben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjita","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Catey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"4338_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/pharmaceutics15020546","volume":"15","author":"Y Tian","year":"2023","unstructured":"Tian Y, Liu Z, Wang J, Li L, Wang F, Zhu Z, et al. Nanomedicine for combination urologic cancer immunotherapy. Pharmaceutics. 2023;15:546. https:\/\/doi.org\/10.3390\/pharmaceutics15020546.","journal-title":"Pharmaceutics"},{"key":"4338_CR2","doi-asserted-by":"publisher","first-page":"e10353","DOI":"10.1002\/btm2.10353","volume":"8","author":"M Ashrafizadeh","year":"2023","unstructured":"Ashrafizadeh M, Zarrabi A, Karimi-Maleh H, Taheriazam A, Mirzaei S, Hashemi M, et al. (nano)platforms in bladder cancer therapy: challenges and opportunities. Bioeng Transl Med. 2023;8:e10353. https:\/\/doi.org\/10.1002\/btm2.10353.","journal-title":"Bioeng Transl Med"},{"key":"4338_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","volume":"14","author":"Z Cheng","year":"2021","unstructured":"Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14:85. https:\/\/doi.org\/10.1186\/s13045-021-01096-0.","journal-title":"J Hematol Oncol"},{"key":"4338_CR4","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1186\/s12967-025-07277-6","volume":"23","author":"Y Li","year":"2025","unstructured":"Li Y, Jin L, Tao B, Li X, Shi H, Qin Y, et al. Nanodynamic therapy for cancer: mechanistic innovations, targeting strategies and multimodal treatments. J Transl Med. 2025;23:1300. https:\/\/doi.org\/10.1186\/s12967-025-07277-6.","journal-title":"J Transl Med"},{"key":"4338_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.7150\/ntno.74613","volume":"6","author":"S Mosleh-Shirazi","year":"2022","unstructured":"Mosleh-Shirazi S, Abbasi M, Moaddeli MR, Vaez A, Shafiee M, Kasaee SR, et al. Nanotechnology advances in the detection and treatment of cancer: an overview. Nanotheranostics. 2022;6:400\u201323. https:\/\/doi.org\/10.7150\/ntno.74613.","journal-title":"Nanotheranostics"},{"key":"4338_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396. https:\/\/doi.org\/10.1038\/s41573-018-0006-z.","journal-title":"Nat Rev Drug Discov"},{"key":"4338_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"DJ Irvine","year":"2020","unstructured":"Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20:321\u201334. https:\/\/doi.org\/10.1038\/s41577-019-0269-6.","journal-title":"Nat Rev Immunol"},{"key":"4338_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3389\/fbioe.2020.00592","volume":"8","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Zhong H, Fan Y, Liu Q, Song J, Yao S, et al. Immune and clinical features of CD96 expression in glioma by in silico analysis. Front Bioeng Biotechnol. 2020;8:592. https:\/\/doi.org\/10.3389\/fbioe.2020.00592.","journal-title":"Front Bioeng Biotechnol"},{"key":"4338_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22:824\u201333. https:\/\/doi.org\/10.1016\/j.stem.2018.05.004.","journal-title":"Cell Stem Cell"},{"key":"4338_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1634\/stemcells.2007-0454","volume":"26","author":"F Liotta","year":"2008","unstructured":"Liotta F, Angeli R, Cosmi L, Fil\u00ec L, Manuelli C, Frosali F, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing notch signaling. STEM Cells (Dayt Ohio). 2008;26:279\u201389. https:\/\/doi.org\/10.1634\/stemcells.2007-0454.","journal-title":"STEM Cells (Dayt Ohio)"},{"key":"4338_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561\u201384. https:\/\/doi.org\/10.1038\/nrd4591.","journal-title":"Nat Rev Drug Discov"},{"key":"4338_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360\u201378. https:\/\/doi.org\/10.1038\/s41568-021-00346-0.","journal-title":"Nat Rev Cancer"},{"key":"4338_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14712598.2022.2027904","volume":"22","author":"I Mitsogiannis","year":"2022","unstructured":"Mitsogiannis I, Tzelves L, Dellis A, Issa H, Papatsoris A, Moussa M. Prostate cancer immunotherapy. Expert Opin Biol Ther. 2022;22:577\u201390. https:\/\/doi.org\/10.1080\/14712598.2022.2027904.","journal-title":"Expert Opin Biol Ther"},{"key":"4338_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807\u201321. https:\/\/doi.org\/10.1038\/s41423-020-0488-6.","journal-title":"Cell Mol Immunol"},{"key":"4338_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70:86\u2013104. https:\/\/doi.org\/10.3322\/caac.21596.","journal-title":"CA Cancer J Clin"},{"key":"4338_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8:104. https:\/\/doi.org\/10.1038\/s41392-023-01365-z.","journal-title":"Signal Transduct Target Ther"},{"key":"4338_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","volume":"44","author":"C Pfirschke","year":"2016","unstructured":"Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44:343\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2015.11.024.","journal-title":"Immunity"},{"key":"4338_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.semcancer.2019.07.023","volume":"69","author":"H Khan","year":"2021","unstructured":"Khan H, Ullah H, Martorell M, Valdes SE, Belwal T, Tejada S, et al. Flavonoids nanoparticles in cancer: treatment, prevention and clinical prospects. Semin Cancer Biol. 2021;69:200\u201311. https:\/\/doi.org\/10.1016\/j.semcancer.2019.07.023.","journal-title":"Semin Cancer Biol"},{"key":"4338_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41551-022-00846-w","volume":"6","author":"K Ni","year":"2022","unstructured":"Ni K, Xu Z, Culbert A, Luo T, Guo N, Yang K, et al. Synergistic checkpoint-blockade and radiotherapy-radiodynamic therapy via an immunomodulatory nanoscale metal-organic framework. Nat Biomed Eng. 2022;6:144\u201356. https:\/\/doi.org\/10.1038\/s41551-022-00846-w.","journal-title":"Nat Biomed Eng"},{"key":"4338_CR20","doi-asserted-by":"publisher","first-page":"9459","DOI":"10.2147\/IJN.S466396","volume":"19","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Wang C, Zu C, Rong X, Yu Q, Jiang J. Synergistic potential of nanomedicine in prostate cancer immunotherapy: breakthroughs and prospects. Int J Nanomed. 2024;19:9459\u201386. https:\/\/doi.org\/10.2147\/IJN.S466396.","journal-title":"Int J Nanomed"},{"key":"4338_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","volume":"181","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181:151\u201367. https:\/\/doi.org\/10.1016\/j.cell.2020.02.001.","journal-title":"Cell"},{"key":"4338_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7150\/thno.77233","volume":"13","author":"Y-H Wu","year":"2023","unstructured":"Wu Y-H, Chen R-J, Chiu H-W, Yang L-X, Wang Y-L, Chen Y-Y, et al. Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy. Theranostics. 2023;13:40\u201358. https:\/\/doi.org\/10.7150\/thno.77233.","journal-title":"Theranostics"},{"key":"4338_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/17425247.2022.2041598","volume":"19","author":"M Ashrafizadeh","year":"2022","unstructured":"Ashrafizadeh M, Saebfar H, Gholami MH, Hushmandi K, Zabolian A, Bikarannejad P, et al. Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance. Expert Opin Drug Delivery. 2022;19:355\u201382. https:\/\/doi.org\/10.1080\/17425247.2022.2041598.","journal-title":"Expert Opin Drug Delivery"},{"key":"4338_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.drudis.2021.09.020","volume":"27","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, et al. Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects. Drug Discovery Today. 2022;27:436\u201355. https:\/\/doi.org\/10.1016\/j.drudis.2021.09.020.","journal-title":"Drug Discovery Today"},{"key":"4338_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","volume":"17","author":"Q Lu","year":"2024","unstructured":"Lu Q, Kou D, Lou S, Ashrafizadeh M, Aref AR, Canadas I, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol. 2024;17:16. https:\/\/doi.org\/10.1186\/s13045-024-01535-8.","journal-title":"J Hematol Oncol"},{"key":"4338_CR26","doi-asserted-by":"publisher","first-page":"105208","DOI":"10.1016\/j.critrevonc.2026.105208","volume":"221","author":"Z Zhou","year":"2026","unstructured":"Zhou Z, Zhao K, Xiao X, Yang W, Miao Y, Wu T, et al. Natural killer and CAR-NK cell therapies in urological cancers: progress, mechanistic lessons from CAR-T, and future directions. Crit Rev Oncol Hematol. 2026;221:105208. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105208.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4338_CR27","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S1470-2045(17)30327-3","volume":"18","author":"YNS Wong","year":"2017","unstructured":"Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, et al. Evolving adoptive cellular therapies in urological malignancies. Lancet Oncol. 2017;18:e341\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(17)30327-3.","journal-title":"Lancet Oncol"},{"key":"4338_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12951-022-01637-w","volume":"20","author":"X Hu","year":"2022","unstructured":"Hu X, Zhang Y-S, Liu Y-C, Wang N, Zeng X-T, Zhang L-L. Emerging photodynamic\/sonodynamic therapies for urological cancers: progress and challenges. J Nanobiotechnol. 2022;20:437. https:\/\/doi.org\/10.1186\/s12951-022-01637-w.","journal-title":"J Nanobiotechnol"},{"key":"4338_CR29","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.7150\/jca.57334","volume":"12","author":"C Ghosh","year":"2021","unstructured":"Ghosh C, Luong G, Sun Y. A snapshot of the PD-1\/PD-L1 pathway. J Cancer. 2021;12:2735\u201346. https:\/\/doi.org\/10.7150\/jca.57334.","journal-title":"J Cancer"},{"key":"4338_CR30","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/bjc.2013.117","volume":"108","author":"SA Quezada","year":"2013","unstructured":"Quezada SA, Peggs KS, Exploiting. CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer. 2013;108:1560\u20135. https:\/\/doi.org\/10.1038\/bjc.2013.117.","journal-title":"Br J Cancer"},{"key":"4338_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41467-022-35710-7","volume":"14","author":"W Lin","year":"2023","unstructured":"Lin W, Chen L, Zhang H, Qiu X, Huang Q, Wan F, et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat Commun. 2023;14:265. https:\/\/doi.org\/10.1038\/s41467-022-35710-7.","journal-title":"Nat Commun"},{"key":"4338_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12967-024-05104-y","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang C, Jiang A, Lin A, Liu Z, Cheng X, et al. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J Transl Med. 2024;22:293. https:\/\/doi.org\/10.1186\/s12967-024-05104-y.","journal-title":"J Transl Med"},{"key":"4338_CR33","doi-asserted-by":"publisher","first-page":"961637","DOI":"10.3389\/fonc.2022.961637","volume":"12","author":"G Chen","year":"2022","unstructured":"Chen G, Wu K, Li H, Xia D, He T. Role of hypoxia in the tumor microenvironment and targeted therapy. Front Oncol. 2022;12:961637. https:\/\/doi.org\/10.3389\/fonc.2022.961637.","journal-title":"Front Oncol"},{"key":"4338_CR34","doi-asserted-by":"publisher","first-page":"1472772","DOI":"10.3389\/fimmu.2024.1472772","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang L, Zhang L, Zhang Z, Wu P, Zhang Y, Chen X. Advances in targeting tumor microenvironment for immunotherapy. Front Immunol. 2024;15:1472772. https:\/\/doi.org\/10.3389\/fimmu.2024.1472772.","journal-title":"Front Immunol"},{"key":"4338_CR35","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.3390\/curroncol31070283","volume":"31","author":"B Garlisi","year":"2024","unstructured":"Garlisi B, Lauks S, Aitken C, Ogilvie LM, Lockington C, Petrik D, et al. The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities. Curr Oncol Tor Ont. 2024;31:3826\u201344. https:\/\/doi.org\/10.3390\/curroncol31070283.","journal-title":"Curr Oncol Tor Ont"},{"key":"4338_CR36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-13-0214","volume":"2","author":"M Oft","year":"2014","unstructured":"Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2014;2:194\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0214.","journal-title":"Cancer Immunol Res"},{"key":"4338_CR37","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3389\/fimmu.2018.01947","volume":"9","author":"E Littwitz-Salomon","year":"2018","unstructured":"Littwitz-Salomon E, Malyshkina A, Schimmer S, Dittmer U. The cytotoxic activity of natural killer cells is suppressed by IL-10\u2009+\u2009regulatory T cells during acute retroviral infection. Front Immunol. 2018;9:1947. https:\/\/doi.org\/10.3389\/fimmu.2018.01947.","journal-title":"Front Immunol"},{"key":"4338_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","volume":"72","author":"KM Sullivan","year":"2023","unstructured":"Sullivan KM, Jiang X, Guha P, Lausted C, Carter JA, Hsu C, et al. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut. 2023;72:325\u201337. https:\/\/doi.org\/10.1136\/gutjnl-2021-325808.","journal-title":"Gut"},{"key":"4338_CR39","doi-asserted-by":"publisher","unstructured":"Oussa NAE, Dahmani A, Gomis M, Richaud M, Andreev E, Navab-Daneshmand A-R et al. VEGF requires the receptor NRP-1 to inhibit lipopolysaccharide-dependent dendritic cell maturation. J Immunol. Baltimore, Md.: 1950; 2016;197:3927\u201335. https:\/\/doi.org\/10.4049\/jimmunol.1601116","DOI":"10.4049\/jimmunol.1601116"},{"key":"4338_CR40","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo Y, Xie Y-Q, Gao M, Zhao Y, Franco F, Wenes M, et al. Metabolic reprogramming of terminally exhausted CD8\u2009+\u2009T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021;22:746\u201356. https:\/\/doi.org\/10.1038\/s41590-021-00940-2.","journal-title":"Nat Immunol"},{"key":"4338_CR41","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3389\/fimmu.2019.01023","volume":"10","author":"RB de Aguiar","year":"2019","unstructured":"de Aguiar RB, de Moraes JZ. Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors. Front Immunol. 2019;10:1023. https:\/\/doi.org\/10.3389\/fimmu.2019.01023.","journal-title":"Front Immunol"},{"key":"4338_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-025-00880-1","volume":"14","author":"T Tong","year":"2026","unstructured":"Tong T, Guan Y, Luo J, Yan B, Yang X, Zhang J, et al. Targeting YAP1-CD70 axis potentiates the efficacy of anti-PD-1 therapy in prostate cancer. Biomark Res. 2026;14:6. https:\/\/doi.org\/10.1186\/s40364-025-00880-1.","journal-title":"Biomark Res"},{"key":"4338_CR43","doi-asserted-by":"publisher","first-page":"e2413732122","DOI":"10.1073\/pnas.2413732122","volume":"122","author":"R Sun","year":"2025","unstructured":"Sun R, Jiang P, Wang Z, Yan B, Zhu S, Huang Z, et al. DNA2 protein destruction dictates DNA hyperexcision, cGAS-STING activation, and innate immune response in CDK12-deregulated cancers. Proc Natl Acad Sci U S A. 2025;122:e2413732122. https:\/\/doi.org\/10.1073\/pnas.2413732122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4338_CR44","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1038\/s41388-025-03548-0","volume":"44","author":"T Tong","year":"2025","unstructured":"Tong T, Lei H, Huang M, Yang Z, Dai X, Zou H, et al. HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer. Oncogene. 2025;44:3895\u2013908. https:\/\/doi.org\/10.1038\/s41388-025-03548-0.","journal-title":"Oncogene"},{"key":"4338_CR45","doi-asserted-by":"publisher","first-page":"2373526","DOI":"10.1080\/2162402X.2024.2373526","volume":"13","author":"Z Xu","year":"2024","unstructured":"Xu Z, Xiao Z-X, Wang J, Qiu H-W, Cao F, Zhang S-Q, et al. Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity. Oncoimmunology. 2024;13:2373526. https:\/\/doi.org\/10.1080\/2162402X.2024.2373526.","journal-title":"Oncoimmunology"},{"key":"4338_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","volume":"24","author":"Y-T Liu","year":"2025","unstructured":"Liu Y-T, Wang Y-L, Wang S, Li J-J, He W, Fan X-J, et al. Turning cold tumors into hot tumors to ignite immunotherapy. Mol Cancer. 2025;24:254. https:\/\/doi.org\/10.1186\/s12943-025-02477-6.","journal-title":"Mol Cancer"},{"key":"4338_CR47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10238-025-01944-0","volume":"26","author":"M Li","year":"2025","unstructured":"Li M, Kwantwi LB, Wang C, Xiao Q. Tumor microenvironment-mediated immune evasion and resistance in prostate cancer: mechanisms, cross-talk, and therapeutic opportunities. Clin Exp Med. 2025;26:60. https:\/\/doi.org\/10.1007\/s10238-025-01944-0.","journal-title":"Clin Exp Med"},{"key":"4338_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y \u015eenbabao\u011flu","year":"2016","unstructured":"\u015eenbabao\u011flu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17:231. https:\/\/doi.org\/10.1186\/s13059-016-1092-z.","journal-title":"Genome Biol"},{"key":"4338_CR49","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613683.","journal-title":"N Engl J Med"},{"key":"4338_CR50","doi-asserted-by":"publisher","first-page":"1609871","DOI":"10.3389\/fimmu.2025.1609871","volume":"16","author":"L Meng","year":"2025","unstructured":"Meng L, Zhu X, Ji X, Wang B, Zhang H, Zhang G, et al. Advances in the immunological microenvironment and immunotherapy of bladder cancer. Front Immunol. 2025;16:1609871. https:\/\/doi.org\/10.3389\/fimmu.2025.1609871.","journal-title":"Front Immunol"},{"key":"4338_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","volume":"23","author":"Q Liu","year":"2024","unstructured":"Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: the all-around warrior in immunotherapy. Mol Cancer. 2024;23:183. https:\/\/doi.org\/10.1186\/s12943-024-02095-8.","journal-title":"Mol Cancer"},{"key":"4338_CR52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","volume":"13","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers. 2021;13:131. https:\/\/doi.org\/10.3390\/cancers13010131.","journal-title":"Cancers"},{"key":"4338_CR53","doi-asserted-by":"publisher","first-page":"101611","DOI":"10.1016\/j.esmoop.2023.101611","volume":"8","author":"M Ferreiro-Pant\u00edn","year":"2023","unstructured":"Ferreiro-Pant\u00edn M, Anido-Herranz U, Betancor YZ, Cebey-L\u00f3pez V, Le\u00f3n-Mateos L, Garc\u00eda-Gonz\u00e1lez J, et al. Clinical, molecular, and immune correlates of the immunotherapy response score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial. ESMO Open. 2023;8:101611. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101611.","journal-title":"ESMO Open"},{"key":"4338_CR54","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1510665.","journal-title":"N Engl J Med"},{"key":"4338_CR55","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S1470-2045(23)00449-7","volume":"24","author":"M-O Grimm","year":"2023","unstructured":"Grimm M-O, Esteban E, Barth\u00e9l\u00e9my P, Schmidinger M, Busch J, Valderrama BP, et al. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023;24:1252\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(23)00449-7.","journal-title":"Lancet Oncol"},{"key":"4338_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","volume":"81","author":"L Albiges","year":"2022","unstructured":"Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barth\u00e9l\u00e9my P, et al. First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial. Eur Urol. 2022;81:266\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2021.10.001.","journal-title":"Eur Urol"},{"key":"4338_CR57","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(14)70189-5.","journal-title":"Lancet Oncol"},{"key":"4338_CR58","doi-asserted-by":"publisher","unstructured":"Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. Hagerstown, Md.: 1997; 2007;30:825\u201330. https:\/\/doi.org\/10.1097\/CJI.0b013e318156e47e","DOI":"10.1097\/CJI.0b013e318156e47e"},{"key":"4338_CR59","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eururo.2015.02.032","volume":"68","author":"ED Carosella","year":"2015","unstructured":"Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1\/PD-L1, and HLA-G. Eur Urol. 2015;68:267\u201379. https:\/\/doi.org\/10.1016\/j.eururo.2015.02.032.","journal-title":"Eur Urol"},{"key":"4338_CR60","doi-asserted-by":"publisher","first-page":"2395680","DOI":"10.1080\/21645515.2024.2395680","volume":"20","author":"TP Tonelli","year":"2024","unstructured":"Tonelli TP, Eickhoff JC, Johnson LE, Liu G, McNeel DG. Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer. Hum Vaccin Immunother. 2024;20:2395680. https:\/\/doi.org\/10.1080\/21645515.2024.2395680.","journal-title":"Hum Vaccin Immunother"},{"key":"4338_CR61","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00262-006-0241-8","volume":"56","author":"LE Johnson","year":"2007","unstructured":"Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8\u2009+\u2009T cells. Cancer Immunol Immunother: CII. 2007;56:885\u201395. https:\/\/doi.org\/10.1007\/s00262-006-0241-8.","journal-title":"Cancer Immunol Immunother: CII"},{"key":"4338_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02483-1","author":"YT M I","year":"2020","unstructured":"M I YT. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunol Immunother: CII [Internet] Cancer Immunol Immunother. 2020. https:\/\/doi.org\/10.1007\/s00262-020-02483-1. [cited 2026 Feb 6];69.","journal-title":"Cancer Immunol Immunother: CII [Internet] Cancer Immunol Immunother"},{"key":"4338_CR63","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1634\/theoncologist.2019-0608","volume":"25","author":"ME Gatti-Mays","year":"2020","unstructured":"Gatti-Mays ME, Redman JM, Donahue RN, Palena C, Madan RA, Karzai F, et al. A phase I trial using a multitargeted recombinant adenovirus 5 (CEA\/MUC1\/brachyury)-based immunotherapy vaccine regimen in patients with advanced cancer. Oncologist. 2020;25:479\u2013e899. https:\/\/doi.org\/10.1634\/theoncologist.2019-0608.","journal-title":"Oncologist"},{"key":"4338_CR64","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung I-Y, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724\u201334. https:\/\/doi.org\/10.1038\/s41591-022-01726-1.","journal-title":"Nat Med"},{"key":"4338_CR65","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/pros.20608","volume":"67","author":"A Morgenroth","year":"2007","unstructured":"Morgenroth A, Cartellieri M, Schmitz M, G\u00fcnes S, Weigle B, Bachmann M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 2007;67:1121\u201331. https:\/\/doi.org\/10.1002\/pros.20608.","journal-title":"Prostate"},{"key":"4338_CR66","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/cancers14030503","volume":"14","author":"MPJ Perera","year":"2022","unstructured":"Perera MPJ, Thomas PB, Risbridger GP, Taylor R, Azad A, Hofman MS, et al. Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate cancer. Cancers. 2022;14:503. https:\/\/doi.org\/10.3390\/cancers14030503.","journal-title":"Cancers"},{"key":"4338_CR67","doi-asserted-by":"publisher","unstructured":"Rocha SM, Socorro S, Passarinha LA, Maia CJ. Comprehensive landscape of STEAP family members expression in human cancers: unraveling the potential usefulness in clinical practice using integrated bioinformatics analysis. DATA [Internet]. publisher; 2022 [cited 2026 Feb 6];7. https:\/\/doi.org\/10.3390\/data7050064","DOI":"10.3390\/data7050064"},{"key":"4338_CR68","doi-asserted-by":"publisher","first-page":"14523","DOI":"10.1073\/pnas.96.25.14523","volume":"96","author":"RS Hubert","year":"1999","unstructured":"Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A. 1999;96:14523\u20138. https:\/\/doi.org\/10.1073\/pnas.96.25.14523.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4338_CR69","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","volume":"14","author":"V Bhatia","year":"2023","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu L-T, Tsao A, Sasaki K, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14:2041. https:\/\/doi.org\/10.1038\/s41467-023-37874-2.","journal-title":"Nat Commun"},{"key":"4338_CR70","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.3390\/biomedicines13102545","volume":"13","author":"ML Calabr\u00f2","year":"2025","unstructured":"Calabr\u00f2 ML, Ettari R, Di Chio C, De Luca F, Previti S, Zappal\u00e0 M. CAR-T cell therapy for prostate cancer: current advances and future perspectives. Biomedicines. 2025;13:2545. https:\/\/doi.org\/10.3390\/biomedicines13102545.","journal-title":"Biomedicines"},{"key":"4338_CR71","doi-asserted-by":"publisher","first-page":"e169655","DOI":"10.1172\/JCI169655","volume":"133","author":"P Zanvit","year":"2023","unstructured":"Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold JM, et al. Antitumor activity of AZD0754, a dnTGF\u03b2RII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. J Clin Invest. 2023;133:e169655. https:\/\/doi.org\/10.1172\/JCI169655.","journal-title":"J Clin Invest"},{"key":"4338_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00394-5","author":"H Ei","year":"2021","unstructured":"Ei H, Je R. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev, Urol [Internet]. Nat Rev Urol. 2021. https:\/\/doi.org\/10.1038\/s41585-020-00394-5. [cited 2026 Feb 6];18.","journal-title":"Nat Rev Urol"},{"key":"4338_CR73","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CU9.0000000000000219","volume":"17","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Sun X, Song X, Li Z, Zhang P, Zhang W, et al. Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy. Curr Urol. 2023;17:221\u20138. https:\/\/doi.org\/10.1097\/CU9.0000000000000219.","journal-title":"Curr Urol"},{"key":"4338_CR74","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3390\/cells9061382","volume":"9","author":"IM Montagner","year":"2020","unstructured":"Montagner IM, Penna A, Fracasso G, Carpanese D, Dalla Piet\u00e0 A, Barbieri V, et al. Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer. Cells. 2020;9:1382. https:\/\/doi.org\/10.3390\/cells9061382.","journal-title":"Cells"},{"key":"4338_CR75","doi-asserted-by":"publisher","first-page":"6915912","DOI":"10.1155\/2017\/6915912","volume":"2017","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Tian K, Xu J, Zhang H, Li L, Fu Q, et al. Synergistic effects of cabozantinib and EGFR-specific CAR-NK-92 cells in renal cell carcinoma. J Immunol Res. 2017;2017:6915912. https:\/\/doi.org\/10.1155\/2017\/6915912.","journal-title":"J Immunol Res"},{"key":"4338_CR76","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","volume":"14","author":"SK Pal","year":"2024","unstructured":"Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 2024;14:1176\u201389. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0102.","journal-title":"Cancer Discov"},{"key":"4338_CR77","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-med-070623-045906","volume":"76","author":"PD Zang","year":"2025","unstructured":"Zang PD, Angeles A, Pal SK. CD70: an emerging anticancer target in renal cell carcinoma and beyond. Annu Rev Med. 2025;76:257\u201366. https:\/\/doi.org\/10.1146\/annurev-med-070623-045906.","journal-title":"Annu Rev Med"},{"key":"4338_CR78","doi-asserted-by":"publisher","first-page":"e1476816","DOI":"10.1080\/2162402X.2018.1476816","volume":"7","author":"M Poch","year":"2018","unstructured":"Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, et al. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018;7:e1476816. https:\/\/doi.org\/10.1080\/2162402X.2018.1476816.","journal-title":"Oncoimmunology"},{"key":"4338_CR79","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/cncr.23552","volume":"113","author":"JA Klapper","year":"2008","unstructured":"Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the national cancer institute between 1986 and 2006. Cancer. 2008;113:293\u2013301. https:\/\/doi.org\/10.1002\/cncr.23552.","journal-title":"Cancer"},{"key":"4338_CR80","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1097\/01.ju.0000109742.88380.a2","volume":"171","author":"MA O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell MA, Luo Y, Hunter SE, Chen X, Hayes LL, Clinton SK. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. J Urol. 2004;171:1330\u20135. https:\/\/doi.org\/10.1097\/01.ju.0000109742.88380.a2.","journal-title":"J Urol"},{"key":"4338_CR81","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(05)67677-X","volume":"163","author":"M Eto","year":"2000","unstructured":"Eto M, Harada M, Tamada K, Tokuda N, Koikawa Y, Nakamura M, et al. Antitumor activity of interleukin-12 against murine bladder cancer. J Urol. 2000;163:1549\u201352. https:\/\/doi.org\/10.1016\/S0022-5347(05)67677-X.","journal-title":"J Urol"},{"key":"4338_CR82","doi-asserted-by":"publisher","first-page":"621550","DOI":"10.3389\/fonc.2021.621550","volume":"11","author":"AM Esteves","year":"2021","unstructured":"Esteves AM, Papaevangelou E, Dasgupta P, Galustian C. Combination of interleukin-15 with a STING agonist, ADU-S100 analog: a potential immunotherapy for prostate cancer. Front Oncol. 2021;11:621550. https:\/\/doi.org\/10.3389\/fonc.2021.621550.","journal-title":"Front Oncol"},{"key":"4338_CR83","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","volume":"49","author":"A Marcus","year":"2018","unstructured":"Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018;49:754\u2013e7634. https:\/\/doi.org\/10.1016\/j.immuni.2018.09.016.","journal-title":"Immunity"},{"key":"4338_CR84","doi-asserted-by":"publisher","first-page":"eaaz2738","DOI":"10.1126\/sciimmunol.aaz2738","volume":"5","author":"CJ Nicolai","year":"2020","unstructured":"Nicolai CJ, Wolf N, Chang I-C, Kirn G, Marcus A, Ndubaku CO, et al. NK cells mediate clearance of CD8\u2009+\u2009T cell-resistant tumors in response to STING agonists. Sci Immunol. 2020;5:eaaz2738. https:\/\/doi.org\/10.1126\/sciimmunol.aaz2738.","journal-title":"Sci Immunol"},{"key":"4338_CR85","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.urolonc.2022.10.009","volume":"41","author":"P Maisch","year":"2023","unstructured":"Maisch P, Koll F, Bolenz C, Chun FK-H, Gschwend JE, Schmid SC. Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: a systematic review and meta-analysis. Urol Oncol. 2023;41:219\u201332. https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.009.","journal-title":"Urol Oncol"},{"key":"4338_CR86","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2309863.","journal-title":"N Engl J Med"},{"key":"4338_CR87","doi-asserted-by":"publisher","first-page":"102261","DOI":"10.1016\/j.clgc.2024.102261","volume":"23","author":"T Powles","year":"2025","unstructured":"Powles T, Cs\u0151szi T, Loriot Y, Matsubara N, Geczi L, Cheng SY-S, et al. Cisplatin- or carboplatin-based chemotherapy plus pembrolizumab in advanced urothelial cancer: exploratory analysis from the phase 3 KEYNOTE-361 study. Clin Genitourin Cancer. 2025;23:102261. https:\/\/doi.org\/10.1016\/j.clgc.2024.102261.","journal-title":"Clin Genitourin Cancer"},{"key":"4338_CR88","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3389\/fimmu.2020.01333","volume":"11","author":"L Qin","year":"2020","unstructured":"Qin L, Wang S, Dominguez D, Long A, Chen S, Fan J, et al. Development of spherical nucleic acids for prostate cancer immunotherapy. Front Immunol. 2020;11:1333. https:\/\/doi.org\/10.3389\/fimmu.2020.01333.","journal-title":"Front Immunol"},{"key":"4338_CR89","doi-asserted-by":"publisher","first-page":"1600013","DOI":"10.1002\/adbi.201600013","volume":"1","author":"ST Koshy","year":"2017","unstructured":"Koshy ST, Cheung AS, Gu L, Graveline AR, Mooney DJ. Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy. Adv Biosyst. 2017;1:1600013. https:\/\/doi.org\/10.1002\/adbi.201600013.","journal-title":"Adv Biosyst"},{"key":"4338_CR90","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1038\/s41467-024-54293-z","volume":"15","author":"H Choi","year":"2024","unstructured":"Choi H, Jeong S-H, Sim\u00f3 C, Bakenecker A, Liop J, Lee HS, et al. Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy. Nat Commun. 2024;15:9934. https:\/\/doi.org\/10.1038\/s41467-024-54293-z.","journal-title":"Nat Commun"},{"key":"4338_CR91","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/pharmaceutics11120652","volume":"11","author":"HY Yoon","year":"2019","unstructured":"Yoon HY, Yang HM, Kim CH, Goo YT, Hwang GY, Chang IH, et al. Enhanced intracellular delivery of BCG cell wall skeleton into bladder cancer cells using liposomes functionalized with folic acid and pep-1 peptide. Pharmaceutics. 2019;11:652. https:\/\/doi.org\/10.3390\/pharmaceutics11120652.","journal-title":"Pharmaceutics"},{"key":"4338_CR92","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.02.034","volume":"164","author":"H Kim","year":"2018","unstructured":"Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, et al. Polymeric nanoparticles encapsulating novel TLR7\/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials. 2018;164:38\u201353. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.02.034.","journal-title":"Biomaterials"},{"key":"4338_CR93","doi-asserted-by":"publisher","first-page":"8606","DOI":"10.1038\/s41598-017-09116-1","volume":"7","author":"Y Liu","year":"2017","unstructured":"Liu Y, Maccarini P, Palmer GM, Etienne W, Zhao Y, Lee C-T, et al. Synergistic immuno photothermal nanotherapy (SYMPHONY) for the treatment of unresectable and metastatic cancers. Sci Rep. 2017;7:8606. https:\/\/doi.org\/10.1038\/s41598-017-09116-1.","journal-title":"Sci Rep"},{"key":"4338_CR94","doi-asserted-by":"publisher","first-page":"eado7373","DOI":"10.1126\/sciadv.ado7373","volume":"11","author":"W Yang","year":"2025","unstructured":"Yang W, Di S, Yang Z, Cao J, Fu Q, Ren H, et al. One-dimensional nanosonosensitizer boosted multiple branches of immune responses against MHC-deficient immune-evasive urologic tumor. Sci Adv. 2025;11:eado7373. https:\/\/doi.org\/10.1126\/sciadv.ado7373.","journal-title":"Sci Adv"},{"key":"4338_CR95","doi-asserted-by":"publisher","unstructured":"Chen C-C, Fa Y-C, Kuo Y-Y, Liu Y-C, Lin C-Y, Wang X-H et al. Thiolated mesoporous silica nanoparticles as an immunoadjuvant to enhance efficacy of intravesical chemotherapy for bladder cancer. Adv Sci. Weinheim, Baden-Wurttemberg, Germany; 2023;10:e2204643. https:\/\/doi.org\/10.1002\/advs.202204643","DOI":"10.1002\/advs.202204643"},{"key":"4338_CR96","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12645-023-00200-y","volume":"14","author":"S Huang","year":"2023","unstructured":"Huang S, Yuan J, Xie Y, Qing K, Shi Z, Chen G, et al. Targeting nano-regulator based on metal\u2013organic frameworks for enhanced immunotherapy of bone metastatic prostate cancer. Cancer Nanotechnol. 2023;14:43. https:\/\/doi.org\/10.1186\/s12645-023-00200-y.","journal-title":"Cancer Nanotechnol"},{"key":"4338_CR97","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12951-024-02458-9","volume":"22","author":"Y Guo","year":"2024","unstructured":"Guo Y, Wu J, Chen L, Liu L, Bi T, Pan Y, et al. Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy. J Nanobiotechnol. 2024;22:192. https:\/\/doi.org\/10.1186\/s12951-024-02458-9.","journal-title":"J Nanobiotechnol"},{"key":"4338_CR98","doi-asserted-by":"publisher","first-page":"e2101262","DOI":"10.1002\/adhm.202101262","volume":"10","author":"MH Teplensky","year":"2021","unstructured":"Teplensky MH, Dittmar JW, Qin L, Wang S, Evangelopoulos M, Zhang B, et al. Spherical nucleic acid vaccine structure markedly influences adaptive immune responses of clinically utilized prostate cancer targets. Adv Healthc Mater. 2021;10:e2101262. https:\/\/doi.org\/10.1002\/adhm.202101262.","journal-title":"Adv Healthc Mater"},{"issue":"3","key":"4338_CR99","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1515\/mr-2023-0002","volume":"2023","author":"H Ding","year":"2021","unstructured":"Ding H, Zhang Y, Mao Y, Li Y, Shen Y, Sheng J, et al. Modulation of macrophage polarization by iron-based nanoparticles. Med Rev. 2021;2023(3):105\u201322. https:\/\/doi.org\/10.1515\/mr-2023-0002.","journal-title":"Med Rev"},{"key":"4338_CR100","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/nnano.2016.168","volume":"11","author":"S Zanganeh","year":"2016","unstructured":"Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11:986\u201394. https:\/\/doi.org\/10.1038\/nnano.2016.168.","journal-title":"Nat Nanotechnol"},{"key":"4338_CR101","doi-asserted-by":"publisher","first-page":"108053","DOI":"10.1016\/j.celrep.2020.108053","volume":"32","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Ma Z, Wang B, Guan Y, Su X-D, Jiang Z. Mn2\u2009+\u2009directly activates cGAS and structural analysis suggests Mn2\u2009+\u2009induces a noncanonical catalytic synthesis of 2\u20193\u2019-cGAMP. Cell Rep. 2020;32:108053. https:\/\/doi.org\/10.1016\/j.celrep.2020.108053.","journal-title":"Cell Rep"},{"key":"4338_CR102","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40824-023-00374-x","volume":"27","author":"Q He","year":"2023","unstructured":"He Q, Zheng R, Ma J, Zhao L, Shi Y, Qiu J. Responsive manganese-based nanoplatform amplifying cGAS-STING activation for immunotherapy. Biomater Res. 2023;27:29. https:\/\/doi.org\/10.1186\/s40824-023-00374-x.","journal-title":"Biomater Res"},{"key":"4338_CR103","doi-asserted-by":"publisher","first-page":"e202551771","DOI":"10.1002\/eji.202551771","volume":"55","author":"Y-H Kim","year":"2025","unstructured":"Kim Y-H, Panda AK, Shevach EM. Treg control of CD80\/CD86 expression mediates immune system homeostasis. Eur J Immunol. 2025;55:e202551771. https:\/\/doi.org\/10.1002\/eji.202551771.","journal-title":"Eur J Immunol"},{"key":"4338_CR104","doi-asserted-by":"publisher","first-page":"114410","DOI":"10.1016\/j.jconrel.2025.114410","volume":"389","author":"S Kodamasimham","year":"2026","unstructured":"Kodamasimham S, Ju HH, Zhou X, Haggag Y, Huang C, Ha B, et al. Controlled delivery of STING agonist and manganese ion in injectable PLGA implants for enhanced cancer immunotherapy. J Control Release: Off J Control Release Soc. 2026;389:114410. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114410.","journal-title":"J Control Release: Off J Control Release Soc"},{"key":"4338_CR105","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1479-5876-8-4","volume":"8","author":"P Jin","year":"2010","unstructured":"Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, et al. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med. 2010;8:4. https:\/\/doi.org\/10.1186\/1479-5876-8-4.","journal-title":"J Transl Med"},{"key":"4338_CR106","doi-asserted-by":"publisher","first-page":"102133","DOI":"10.1016\/j.mtbio.2025.102133","volume":"34","author":"J Li","year":"2025","unstructured":"Li J, Pang X, Xin Z, Song L, Liu X, Zhang X, et al. Engineered anti-cancer nanomedicine for synergistic cuproptosis-immunotherapy. Mater Today Bio. 2025;34:102133. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102133.","journal-title":"Mater Today Bio"},{"key":"4338_CR107","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1016\/j.apsb.2025.07.007","volume":"15","author":"R Zhang","year":"2025","unstructured":"Zhang R, Li Y, Fu H, Zhao C, Li X, Wang Y, et al. Nanomedicine strategies for cuproptosis: metabolic reprogramming and tumor immunotherapy. Acta Pharm Sin B. 2025;15:4582\u2013613. https:\/\/doi.org\/10.1016\/j.apsb.2025.07.007.","journal-title":"Acta Pharm Sin B"},{"key":"4338_CR108","doi-asserted-by":"publisher","first-page":"123626","DOI":"10.1016\/j.biomaterials.2025.123626","volume":"325","author":"X Zhan","year":"2026","unstructured":"Zhan X, Xiao H, Zhang X, Li S, Zhang W, Ma L, et al. A metallic metabolic nano-regulator reprograms the PKM2\/HIF-1\u03b1\/DLAT axis to amplify tumor-specific cuproptosis. Biomaterials. 2026;325:123626. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123626.","journal-title":"Biomaterials"},{"key":"4338_CR109","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12964-024-01743-2","volume":"22","author":"R Zhao","year":"2024","unstructured":"Zhao R, Sukocheva O, Tse E, Neganova M, Aleksandrova Y, Zheng Y, et al. Cuproptosis, the novel type of oxidation-induced cell death in thoracic cancers: can it enhance the success of immunotherapy? Cell Commun Signal: CCS. 2024;22:379. https:\/\/doi.org\/10.1186\/s12964-024-01743-2.","journal-title":"Cell Commun Signal: CCS"},{"key":"4338_CR110","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-025-02315-9","volume":"24","author":"X Zhou","year":"2025","unstructured":"Zhou X, Li R, Lai M, Lai C. Exploring molecular and cellular mechanisms of pre-metastatic niche in renal cell carcinoma. Mol Cancer. 2025;24:121. https:\/\/doi.org\/10.1186\/s12943-025-02315-9.","journal-title":"Mol Cancer"},{"key":"4338_CR111","doi-asserted-by":"publisher","first-page":"115322","DOI":"10.1016\/j.intimp.2025.115322","volume":"163","author":"Z Li","year":"2025","unstructured":"Li Z, Ma J, Xu M, Duan Y, Huang C, Dai Q, et al. Regulatory T cells in renal cell carcinoma: tumor-promoting mechanisms and emerging therapeutic strategies. Int Immunopharmacol. 2025;163:115322. https:\/\/doi.org\/10.1016\/j.intimp.2025.115322.","journal-title":"Int Immunopharmacol"},{"key":"4338_CR112","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2012.04.049","volume":"62","author":"M Meskawi","year":"2012","unstructured":"Meskawi M, Sun M, Trinh Q-D, Bianchi M, Hansen J, Tian Z, et al. A review of integrated staging systems for renal cell carcinoma. Eur Urol. 2012;62:303\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2012.04.049.","journal-title":"Eur Urol"},{"key":"4338_CR113","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamaoncol.2021.4337","volume":"8","author":"V Navani","year":"2022","unstructured":"Navani V, Heng DYC. Treatment selection in first-line metastatic renal cell carcinoma-the contemporary treatment paradigm in the age of combination therapy: a review. JAMA Oncol. 2022;8:292\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4337.","journal-title":"JAMA Oncol"},{"key":"4338_CR114","doi-asserted-by":"publisher","first-page":"29291","DOI":"10.1021\/acsami.5c03559","volume":"17","author":"M Wu","year":"2025","unstructured":"Wu M, Zhao K, Tao X, Du L, Chen W, Guo H, et al. Biomimetic copper nanozyme reprograms cold tumor via cuproptosis-pyroptosis crosstalk for potent renal carcinoma immunotherapy. ACS Appl Mater Interfaces. 2025;17:29291\u2013304. https:\/\/doi.org\/10.1021\/acsami.5c03559.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4338_CR115","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1038\/s41467-020-18731-y","volume":"11","author":"T-S Hsu","year":"2020","unstructured":"Hsu T-S, Lin Y-L, Wang Y-A, Mo S-T, Chi P-Y, Lai AC-Y, et al. HIF-2\u03b1 is indispensable for regulatory T cell function. Nat Commun. 2020;11:5005. https:\/\/doi.org\/10.1038\/s41467-020-18731-y.","journal-title":"Nat Commun"},{"key":"4338_CR116","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for renal cell carcinoma in von hippel-lindau disease. N Engl J Med. 2021;385:2036\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2103425.","journal-title":"N Engl J Med"},{"key":"4338_CR117","doi-asserted-by":"publisher","first-page":"e2402973","DOI":"10.1002\/adhm.202402973","volume":"13","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Li Y, Li X, Yu Y, Zhang L, Zhang H, et al. Targeting hypoxia and autophagy inhibition via delivering sonodynamic nanoparticles with HIF-2\u03b1 inhibitor for enhancing immunotherapy in renal cell carcinoma. Adv Healthc Mater. 2024;13:e2402973. https:\/\/doi.org\/10.1002\/adhm.202402973.","journal-title":"Adv Healthc Mater"},{"key":"4338_CR118","doi-asserted-by":"publisher","first-page":"e202411498","DOI":"10.1002\/anie.202411498","volume":"63","author":"H Tian","year":"2024","unstructured":"Tian H, Li W, Wang G, Tian Y, Yan J, Yu X, et al. Metal-phenolic nanomaterial with organelle-level precision primes antitumor immunity via mtDNA-dependent cGAS-STING activation. Angew Chem (Int Ed Engl). 2024;63:e202411498. https:\/\/doi.org\/10.1002\/anie.202411498.","journal-title":"Angew Chem (Int Ed Engl)"},{"key":"4338_CR119","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41423-021-00669-w","volume":"18","author":"R Zhang","year":"2021","unstructured":"Zhang R, Wang C, Guan Y, Wei X, Sha M, Yi M, et al. Manganese salts function as potent adjuvants. Cell Mol Immunol. 2021;18:1222\u201334. https:\/\/doi.org\/10.1038\/s41423-021-00669-w.","journal-title":"Cell Mol Immunol"},{"key":"4338_CR120","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/B978-0-12-800092-2.00011-3","volume":"123","author":"SS Skandalis","year":"2014","unstructured":"Skandalis SS, Gialeli C, Theocharis AD, Karamanos NK. Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer. Adv Cancer Res. 2014;123:277\u2013317. https:\/\/doi.org\/10.1016\/B978-0-12-800092-2.00011-3.","journal-title":"Adv Cancer Res"},{"key":"4338_CR121","doi-asserted-by":"publisher","first-page":"e2500141","DOI":"10.1002\/adhm.202500141","volume":"14","author":"Y Du","year":"2025","unstructured":"Du Y, Mai Y, Liu Z, Lin G, Luo S, Guo C, et al. Synergistic provoking of pyroptosis and STING pathway by multifunctional manganese-polydopamine nano-immunomodulator for enhanced renal cell carcinoma immunotherapy. Adv Healthc Mater. 2025;14:e2500141. https:\/\/doi.org\/10.1002\/adhm.202500141.","journal-title":"Adv Healthc Mater"},{"key":"4338_CR122","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s43018-025-00950-1","volume":"6","author":"W Jing","year":"2025","unstructured":"Jing W, Han M, Wang G, Kong Z, Zhao X, Fu Z, et al. An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma. Nat Cancer. 2025;6:838\u201353. https:\/\/doi.org\/10.1038\/s43018-025-00950-1.","journal-title":"Nat Cancer"},{"key":"4338_CR123","doi-asserted-by":"publisher","first-page":"e389650","DOI":"10.1200\/EDBK_389650","volume":"43","author":"CC Fahey","year":"2023","unstructured":"Fahey CC, Shevach JW, Flippot R, Albiges L, Haas NB, Beckermann KE. Triplet strategies in metastatic clear cell renal cell carcinoma: a worthy option in the first-line setting? Am Soc Clin Oncol Educ Book, Am Soc Clin Oncol. Annu Meet. 2023;43:e389650. https:\/\/doi.org\/10.1200\/EDBK_389650.","journal-title":"Annu Meet"},{"key":"4338_CR124","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12943-025-02382-y","volume":"24","author":"KM Au","year":"2025","unstructured":"Au KM, Li S, Zhang T, Wang AZ. Biologically targeted dual adaptive and innate nano-immunotherapy for clear cell renal cell carcinoma treatment. Mol Cancer. 2025;24:181. https:\/\/doi.org\/10.1186\/s12943-025-02382-y.","journal-title":"Mol Cancer"},{"key":"4338_CR125","doi-asserted-by":"publisher","first-page":"102971","DOI":"10.1016\/j.critrevonc.2020.102971","volume":"152","author":"A Parmar","year":"2020","unstructured":"Parmar A, Sander B, Bjarnason GA, Chan KKW. Systemic therapy in metastatic renal cell carcinoma: emerging challenges in therapeutic choice. Crit Rev Oncol Hematol. 2020;152:102971. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102971.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4338_CR126","doi-asserted-by":"publisher","first-page":"122550","DOI":"10.1016\/j.biomaterials.2024.122550","volume":"308","author":"X-H Wu","year":"2024","unstructured":"Wu X-H, Wang J-Q, Wang M-D, Xiao T, Wang Y, Niu J-Y, et al. Bispecific fibrous glue synergistically boosts vascular normalization and antitumor immunity for advanced renal carcinoma therapy. Biomaterials. 2024;308:122550. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122550.","journal-title":"Biomaterials"},{"key":"4338_CR127","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.abb.2016.06.011","volume":"611","author":"ML Ackland","year":"2016","unstructured":"Ackland ML, Michalczyk AA. Zinc and infant nutrition. Arch Biochem Biophys. 2016;611:51\u20137. https:\/\/doi.org\/10.1016\/j.abb.2016.06.011.","journal-title":"Arch Biochem Biophys"},{"key":"4338_CR128","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41563-024-02093-7","volume":"24","author":"X Zeng","year":"2025","unstructured":"Zeng X, Wang Z, Zhao A, Wu Y, Wang Z, Wu A, et al. Zinc nanoparticles from oral supplements accumulate in renal tumours and stimulate antitumour immune responses. Nat Mater. 2025;24:287\u201396. https:\/\/doi.org\/10.1038\/s41563-024-02093-7.","journal-title":"Nat Mater"},{"key":"4338_CR129","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1158\/1078-0432.CCR-19-1614","volume":"26","author":"L Teixeira","year":"2020","unstructured":"Teixeira L, Medioni J, Garibal J, Adotevi O, Doucet L, Durey M-AD, et al. A first-in-human phase I study of INVAC-1, an optimized human telomerase DNA vaccine in patients with advanced solid tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2020;26:588\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1614.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"4338_CR130","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1111\/cas.15044","volume":"112","author":"D Chai","year":"2021","unstructured":"Chai D, Zhang Z, Jiang N, Ding J, Qiu D, Shi SY, et al. Co-immunization with L-myc enhances CD8\u2009+\u2009or CD103\u2009+\u2009DCs mediated tumor-specific multi-functional CD8\u2009+\u2009T cell responses. Cancer Sci. 2021;112:3469\u201383. https:\/\/doi.org\/10.1111\/cas.15044.","journal-title":"Cancer Sci"},{"key":"4338_CR131","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa0810097.","journal-title":"N Engl J Med"},{"key":"4338_CR132","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter S, Vormehr M, van de Roemer N, Diken M, L\u00f6wer M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520:692\u20136. https:\/\/doi.org\/10.1038\/nature14426.","journal-title":"Nature"},{"key":"4338_CR133","doi-asserted-by":"publisher","first-page":"e003101","DOI":"10.1136\/jitc-2021-003101","volume":"9","author":"X He","year":"2021","unstructured":"He X, Zhou S, Dolan M, Shi Y, Wang J, Quinn B, et al. Immunization with short peptide particles reveals a functional CD8\u2009+\u2009T-cell neoepitope in a murine renal carcinoma model. J ImmunoTher Cancer. 2021;9:e003101. https:\/\/doi.org\/10.1136\/jitc-2021-003101.","journal-title":"J ImmunoTher Cancer"},{"key":"4338_CR134","doi-asserted-by":"publisher","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","volume":"4","author":"AO Elmehrath","year":"2021","unstructured":"Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, et al. Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Netw Open. 2021;4:e2119568. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.19568.","journal-title":"JAMA Netw Open"},{"key":"4338_CR135","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.1021\/acs.molpharmaceut.3c00769","volume":"20","author":"Y Sun","year":"2023","unstructured":"Sun Y, Cronin MF, Mendon\u00e7a MCP, Guo J, O\u2019Driscoll CM. M2pep-modified cyclodextrin-siRNA nanoparticles modulate the immunosuppressive tumor microenvironment for prostate cancer therapy. Mol Pharm. 2023;20:5921\u201336. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00769.","journal-title":"Mol Pharm"},{"key":"4338_CR136","doi-asserted-by":"publisher","first-page":"106427","DOI":"10.1016\/j.ejps.2023.106427","volume":"185","author":"Y Sun","year":"2023","unstructured":"Sun Y, Cronin MF, Mendon\u00e7a MCP, Guo J, O\u2019Driscoll CM. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer. Eur J Pharm Sci: Off J Eur Fed Pharm Sci. 2023;185:106427. https:\/\/doi.org\/10.1016\/j.ejps.2023.106427.","journal-title":"Eur J Pharm Sci: Off J Eur Fed Pharm Sci"},{"key":"4338_CR137","doi-asserted-by":"publisher","first-page":"eaba9772","DOI":"10.1126\/scitranslmed.aba9772","volume":"13","author":"Y-X Lin","year":"2021","unstructured":"Lin Y-X, Wang Y, Ding J, Jiang A, Wang J, Yu M, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci Transl Med. 2021;13:eaba9772. https:\/\/doi.org\/10.1126\/scitranslmed.aba9772.","journal-title":"Sci Transl Med"},{"key":"4338_CR138","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1038\/s41467-023-41121-z","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Song A, Yang Q-C, Li S-J, Wang S, Wan S-C, et al. Integration of AIEgens into covalent organic frameworks for pyroptosis and ferroptosis primed cancer immunotherapy. Nat Commun. 2023;14:5355. https:\/\/doi.org\/10.1038\/s41467-023-41121-z.","journal-title":"Nat Commun"},{"key":"4338_CR139","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1038\/s41467-023-40794-w","volume":"14","author":"Y Feng","year":"2023","unstructured":"Feng Y, Luo X, Li Z, Fan X, Wang Y, He R-R, et al. A ferroptosis-targeting ceria anchored halloysite as orally drug delivery system for radiation colitis therapy. Nat Commun. 2023;14:5083. https:\/\/doi.org\/10.1038\/s41467-023-40794-w.","journal-title":"Nat Commun"},{"key":"4338_CR140","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41467-025-57190-1","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li H, Lin J, Li Y, Zhang K, Li H, et al. Engineering nanozyme immunomodulator with magnetic targeting effect for cascade-enzyodynamic and ultrasound-reinforced metallo-immunotherapy in prostate carcinoma. Nat Commun. 2025;16:1876. https:\/\/doi.org\/10.1038\/s41467-025-57190-1.","journal-title":"Nat Commun"},{"key":"4338_CR141","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.1039\/d5tb00478k","volume":"13","author":"Y Yang","year":"2025","unstructured":"Yang Y, Zhao Z, You C, Pang M, Zhong T, Li Q, et al. Lyophilized tumour cell-loaded 10B-doped carbon dots for simultaneous boron neutron capture therapy and enhancement of antitumor immunity of prostate cancer. J Mater Chem B. 2025;13:6701\u201311. https:\/\/doi.org\/10.1039\/d5tb00478k.","journal-title":"J Mater Chem B"},{"key":"4338_CR142","doi-asserted-by":"publisher","first-page":"114283","DOI":"10.1016\/j.jconrel.2025.114283","volume":"388","author":"A Zhang","year":"2025","unstructured":"Zhang A, Zheng J, Xu Y, Fu S, Du Q, Zhao C, et al. Targeting polyamine metabolism induces oxidative\/carbonyl stress to reinvigorate antitumor immunity in prostate cancer. J Control Release: Off J Control Release Soc. 2025;388:114283. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114283.","journal-title":"J Control Release: Off J Control Release Soc"},{"key":"4338_CR143","doi-asserted-by":"publisher","first-page":"e202215307","DOI":"10.1002\/anie.202215307","volume":"62","author":"B Ding","year":"2023","unstructured":"Ding B, Chen H, Tan J, Meng Q, Zheng P, Ma P, et al. ZIF-8 nanoparticles evoke pyroptosis for high-efficiency cancer immunotherapy. Angew Chem (Int Ed Engl). 2023;62:e202215307. https:\/\/doi.org\/10.1002\/anie.202215307.","journal-title":"Angew Chem (Int Ed Engl)"},{"key":"4338_CR144","doi-asserted-by":"publisher","first-page":"e2501542","DOI":"10.1002\/advs.202501542","volume":"12","author":"J Li","year":"2025","unstructured":"Li J, Lv W, Han Z, Li Y, Deng J, Huang Y, et al. Mitoxantrone-encapsulated ZIF-8 enhances chemo-immunotherapy via amplified immunogenic cell death. Adv Sci (Weinh Baden-Wurtt Ger). 2025;12:e2501542. https:\/\/doi.org\/10.1002\/advs.202501542.","journal-title":"Adv Sci (Weinh Baden-Wurtt Ger)"},{"key":"4338_CR145","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1177\/08853282251319473","volume":"39","author":"L Tao","year":"2025","unstructured":"Tao L, Zhang Y, Zhang J, Tao J, Gong Y, Mao J, et al. Peptides-functionalized gold nanostars enhanced degradation of PD-L1 for improved prostate cancer immunotherapy. J Biomater Appl. 2025;39:1188\u2013201. https:\/\/doi.org\/10.1177\/08853282251319473.","journal-title":"J Biomater Appl"},{"key":"4338_CR146","doi-asserted-by":"publisher","first-page":"e2300175","DOI":"10.1002\/advs.202300175","volume":"10","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Liang G, Guo B, Wang W, Yang C, Chen D, et al. Polyphotosensitizer-based nanoparticles with michael addition acceptors inhibiting GST activity and cisplatin deactivation for enhanced chemotherapy and photodynamic immunotherapy. Adv Sci (Weinh Baden-Wurtt Ger). 2023;10:e2300175. https:\/\/doi.org\/10.1002\/advs.202300175.","journal-title":"Adv Sci (Weinh Baden-Wurtt Ger)"},{"key":"4338_CR147","doi-asserted-by":"publisher","first-page":"e2417605","DOI":"10.1002\/advs.202417605","volume":"12","author":"Z Cui","year":"2025","unstructured":"Cui Z, Huang F, Fang K, Yan J, Zhang Y, Kang DD, et al. SCORT-Cas13d nanotherapy precisely targets the undruggable transcription factor HoxB13 in metastatic prostate cancer In vivo. Adv Sci (Weinh Baden-Wurtt Ger). 2025;12:e2417605. https:\/\/doi.org\/10.1002\/advs.202417605.","journal-title":"Adv Sci (Weinh Baden-Wurtt Ger)"},{"key":"4338_CR148","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7:9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0.","journal-title":"Nat Rev Dis Primers"},{"key":"4338_CR149","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1021\/acsnano.4c16981","volume":"19","author":"X Cheng","year":"2025","unstructured":"Cheng X, Xu J, Cui Y, Liu J, Chen Y, He C, et al. Nanovesicles for lipid metabolism reprogram-enhanced ferroptosis and magnetotherapy of refractory tumors and inhibiting metastasis with activated innate immunity. ACS Nano. 2025;19:7213\u201330. https:\/\/doi.org\/10.1021\/acsnano.4c16981.","journal-title":"ACS Nano"},{"key":"4338_CR150","doi-asserted-by":"publisher","first-page":"e2207077","DOI":"10.1002\/smll.202207077","volume":"19","author":"H Wang","year":"2023","unstructured":"Wang H, Guan Y, Li C, Chen J, Yue S, Qian J, et al. PEGylated manganese-zinc ferrite nanocrystals combined with intratumoral implantation of micromagnets enabled synergetic prostate cancer therapy via ferroptotic and immunogenic cell death. Small (Weinh Bergstr Ger). 2023;19:e2207077. https:\/\/doi.org\/10.1002\/smll.202207077.","journal-title":"Small (Weinh Bergstr Ger)"},{"key":"4338_CR151","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1186\/s12951-024-03070-7","volume":"22","author":"B Deng","year":"2024","unstructured":"Deng B, Ke B, Tian Q, Gao Y, Zhai Q, Zhang W. Targeting AURKA with multifunctional nanoparticles in CRPC therapy. J Nanobiotechnol. 2024;22:803. https:\/\/doi.org\/10.1186\/s12951-024-03070-7.","journal-title":"J Nanobiotechnol"},{"key":"4338_CR152","doi-asserted-by":"publisher","first-page":"8998","DOI":"10.1039\/d0nr08024a","volume":"13","author":"X Mu","year":"2021","unstructured":"Mu X, Zhang M, Wei A, Yin F, Wang Y, Hu K, et al. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases. Nanoscale. 2021;13:8998\u20139008. https:\/\/doi.org\/10.1039\/d0nr08024a.","journal-title":"Nanoscale"},{"key":"4338_CR153","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.7150\/thno.99033","volume":"14","author":"Y Liao","year":"2024","unstructured":"Liao Y, Zhao C, Pan Y, Guo Y, Liu L, Wu J, et al. Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy. Theranostics. 2024;14:6409\u201325. https:\/\/doi.org\/10.7150\/thno.99033.","journal-title":"Theranostics"},{"key":"4338_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01982-4","author":"P Sh","year":"2021","unstructured":"Sh P, Kw F, Mc EM, Ge M. Going beyond polycomb: EZH2 functions in prostate cancer. Oncogene [Internet] Oncogene. 2021. https:\/\/doi.org\/10.1038\/s41388-021-01982-4. [cited 2025 Dec 24];40.","journal-title":"Oncogene [Internet] Oncogene"},{"key":"4338_CR155","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12041-021-01327-w","volume":"100","author":"N Gautam","year":"2021","unstructured":"Gautam N, Verma H, Choudhary S, Kaur S, Silakari O. Functional relationship of SNP (Ala490Thr) of an epigenetic gene EZH2 results in the progression and poor survival of ER+\/tamoxifen treated breast cancer patients. J Genet. 2021;100:86.","journal-title":"J Genet"},{"key":"4338_CR156","doi-asserted-by":"publisher","first-page":"156595","DOI":"10.1016\/j.phymed.2025.156595","volume":"141","author":"H Zhang","year":"2025","unstructured":"Zhang H, Du Y, Liu X, Gao R, Xu X, Hou X, et al. Enhancing curcumol delivery through PD-1 targeted nanocarriers: a novel therapeutic approach for prostate cancer. Phytomed. Int J Phytother Phytopharm. 2025;141:156595. https:\/\/doi.org\/10.1016\/j.phymed.2025.156595.","journal-title":"Int J Phytother Phytopharm"},{"key":"4338_CR157","doi-asserted-by":"publisher","first-page":"10724","DOI":"10.1021\/acs.nanolett.4c01610","volume":"24","author":"B Xu","year":"2024","unstructured":"Xu B, Lei H, Tong T, Guan Y, Wang Y, Li B, et al. Acidity-actuated polymer\/calcium phosphate hybrid nanomotor (PCaPmotor) for penetrating drug delivery and synergistic anticancer immunotherapy. Nano Lett. 2024;24:10724\u201333. https:\/\/doi.org\/10.1021\/acs.nanolett.4c01610.","journal-title":"Nano Lett"},{"key":"4338_CR158","doi-asserted-by":"publisher","first-page":"e2415322","DOI":"10.1002\/adma.202415322","volume":"37","author":"L Yin","year":"2025","unstructured":"Yin L, Yang F, Wang W, Zhang L, Cao Z, Shi H, et al. PSMA-targeted nanoparticles with PI3K\/mTOR dual inhibitor downregulate P-glycoprotein and inactivate myeloid-derived suppressor cells for enhanced chemotherapy and immunotherapy in prostate cancer. Adv Mater (Deerf Beach Fla). 2025;37:e2415322. https:\/\/doi.org\/10.1002\/adma.202415322.","journal-title":"Adv Mater (Deerf Beach Fla)"},{"key":"4338_CR159","doi-asserted-by":"publisher","first-page":"e1903462","DOI":"10.1002\/smll.201903462","volume":"15","author":"AM Gasparri","year":"2019","unstructured":"Gasparri AM, Sacchi A, Basso V, Cortesi F, Freschi M, Rrapaj E, et al. Boosting interleukin-12 antitumor activity and synergism with immunotherapy by targeted delivery with isoDGR-tagged nanogold. Small (Weinh Bergstr Ger). 2019;15:e1903462. https:\/\/doi.org\/10.1002\/smll.201903462.","journal-title":"Small (Weinh Bergstr Ger)"},{"key":"4338_CR160","doi-asserted-by":"publisher","first-page":"e2311733","DOI":"10.1002\/adma.202311733","volume":"36","author":"H Wang","year":"2024","unstructured":"Wang H, Jiao D, Feng D, Liu Q, Huang Y, Hou J, et al. Transformable supramolecular self-assembled peptides for cascade self-enhanced ferroptosis primed cancer immunotherapy. Adv Mater (Deerf Beach Fla). 2024;36:e2311733. https:\/\/doi.org\/10.1002\/adma.202311733.","journal-title":"Adv Mater (Deerf Beach Fla)"},{"key":"4338_CR161","doi-asserted-by":"publisher","first-page":"201408","DOI":"10.1103\/PhysRevB.89.201408","volume":"89","author":"AN Rudenko","year":"2014","unstructured":"Rudenko AN, Katsnelson MI. Quasiparticle band structure and tight-binding model for single- and bilayer black phosphorus. Phys Rev B Am Phys Soc. 2014;89:201408. https:\/\/doi.org\/10.1103\/PhysRevB.89.201408.","journal-title":"Phys Rev B Am Phys Soc"},{"key":"4338_CR162","doi-asserted-by":"publisher","first-page":"46801","DOI":"10.1103\/PhysRevLett.114.046801","volume":"114","author":"A Ziletti","year":"2015","unstructured":"Ziletti A, Carvalho A, Campbell DK, Coker DF, Castro Neto AH. Oxygen defects in phosphorene. Phys Rev Lett Am Phys Soc. 2015;114:46801. https:\/\/doi.org\/10.1103\/PhysRevLett.114.046801.","journal-title":"Phys Rev Lett Am Phys Soc"},{"key":"4338_CR163","doi-asserted-by":"publisher","first-page":"214339","DOI":"10.1016\/j.bioadv.2025.214339","volume":"176","author":"X Yan","year":"2025","unstructured":"Yan X, Dong H, Gao L, Liu M, Wang C. Mechanism of selenium-doped black phosphorus nanosheets wrapped with biomimetic tumor cell membrane for prostate cancer immunotherapy. Biomater Adv. 2025;176:214339. https:\/\/doi.org\/10.1016\/j.bioadv.2025.214339.","journal-title":"Biomater Adv"},{"key":"4338_CR164","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12951-022-01248-5","volume":"20","author":"Y Liu","year":"2022","unstructured":"Liu Y, Shang W, Liu H, Hui H, Wu J, Zhang W, et al. Biomimetic manganese-eumelanin nanocomposites for combined hyperthermia-immunotherapy against prostate cancer. J Nanobiotechnol. 2022;20:48. https:\/\/doi.org\/10.1186\/s12951-022-01248-5.","journal-title":"J Nanobiotechnol"},{"key":"4338_CR165","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.2147\/IJN.S301552","volume":"16","author":"W Lin","year":"2021","unstructured":"Lin W, Li C, Xu N, Watanabe M, Xue R, Xu A, et al. Dual-functional PLGA nanoparticles Co-loaded with indocyanine green and resiquimod for prostate cancer treatment. Int J Nanomed. 2021;16:2775\u201387. https:\/\/doi.org\/10.2147\/IJN.S301552.","journal-title":"Int J Nanomed"},{"key":"4338_CR166","doi-asserted-by":"publisher","first-page":"40612","DOI":"10.1021\/acsami.2c09978","volume":"14","author":"J Liu","year":"2022","unstructured":"Liu J, Song Y, Wang Y, Han M, Wang C, Yan F. Cyclodextrin-functionalized gold nanorods loaded with meclofenamic acid for improving N6-methyladenosine-mediated second near-infrared photothermal immunotherapy. ACS Appl Mater Interfaces. 2022;14:40612\u201323. https:\/\/doi.org\/10.1021\/acsami.2c09978.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4338_CR167","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2019;37:1051\u201361. https:\/\/doi.org\/10.1200\/JCO.18.02031.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"4338_CR168","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1001294.","journal-title":"N Engl J Med"},{"key":"4338_CR169","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.coi.2018.03.001","volume":"51","author":"H Maeng","year":"2018","unstructured":"Maeng H, Terabe M, Berzofsky JA. Cancer vaccines: translation from mice to human clinical trials. Curr Opin Immunol. 2018;51:111\u201322. https:\/\/doi.org\/10.1016\/j.coi.2018.03.001.","journal-title":"Curr Opin Immunol"},{"key":"4338_CR170","doi-asserted-by":"publisher","first-page":"209ra152","DOI":"10.1126\/scitranslmed.3006839","volume":"5","author":"SA Jensen","year":"2013","unstructured":"Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013;5:209ra152. https:\/\/doi.org\/10.1126\/scitranslmed.3006839.","journal-title":"Sci Transl Med"},{"key":"4338_CR171","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1073\/pnas.1502850112","volume":"112","author":"AF Radovic-Moreno","year":"2015","unstructured":"Radovic-Moreno AF, Chernyak N, Mader CC, Nallagatla S, Kang RS, Hao L, et al. Immunomodulatory spherical nucleic acids. Proc Natl Acad Sci U S A. 2015;112:3892\u20137. https:\/\/doi.org\/10.1073\/pnas.1502850112.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4338_CR172","doi-asserted-by":"publisher","first-page":"120431","DOI":"10.1016\/j.biomaterials.2020.120431","volume":"266","author":"MA Islam","year":"2021","unstructured":"Islam MA, Rice J, Reesor E, Zope H, Tao W, Lim M, et al. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials. 2021;266:120431. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120431.","journal-title":"Biomaterials"},{"key":"4338_CR173","doi-asserted-by":"publisher","first-page":"1023064","DOI":"10.3389\/fimmu.2023.1023064","volume":"14","author":"N Bowakim-Anta","year":"2023","unstructured":"Bowakim-Anta N, Acolty V, Azouz A, Yagita H, Leo O, Goriely S, et al. Chronic CD27-CD70 costimulation promotes type 1-specific polarization of effector tregs. Front Immunol. 2023;14:1023064. https:\/\/doi.org\/10.3389\/fimmu.2023.1023064.","journal-title":"Front Immunol"},{"key":"4338_CR174","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2217\/imt.15.32","volume":"7","author":"K van de Ven","year":"2015","unstructured":"van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27\/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7:655\u201367. https:\/\/doi.org\/10.2217\/imt.15.32.","journal-title":"Immunotherapy"},{"key":"4338_CR175","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.immuni.2008.10.009","volume":"29","author":"AM Keller","year":"2008","unstructured":"Keller AM, Schildknecht A, Xiao Y, van den Broek M, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8\u2009+\u2009T cell tolerance and permits effective immunity. Immunity. 2008;29:934\u201346. https:\/\/doi.org\/10.1016\/j.immuni.2008.10.009.","journal-title":"Immunity"},{"key":"4338_CR176","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12951-025-03607-4","volume":"23","author":"F Cao","year":"2025","unstructured":"Cao F, Xu Y, Guan Y, Zhang K, Qiu H, Xu Z, et al. Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy. J Nanobiotechnol. 2025;23:523. https:\/\/doi.org\/10.1186\/s12951-025-03607-4.","journal-title":"J Nanobiotechnol"},{"key":"4338_CR177","doi-asserted-by":"publisher","first-page":"7878","DOI":"10.1021\/acsami.2c22363","volume":"15","author":"S Li","year":"2023","unstructured":"Li S, Dong S, Wu J, Lv X, Yang N, Wei Q, et al. Surgically derived cancer cell membrane-coated R837-loaded poly(2-oxazoline) nanoparticles for prostate cancer immunotherapy. ACS Appl Mater Interfaces. 2023;15:7878\u201386. https:\/\/doi.org\/10.1021\/acsami.2c22363.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4338_CR178","doi-asserted-by":"publisher","first-page":"10388","DOI":"10.3390\/ijms251910388","volume":"25","author":"A Winnicka","year":"2024","unstructured":"Winnicka A, Brzeszczy\u0144ska J, Saluk J, Wigner-Jeziorska P. Nanomedicine in bladder cancer therapy. Int J Mol Sci. 2024;25:10388. https:\/\/doi.org\/10.3390\/ijms251910388.","journal-title":"Int J Mol Sci"},{"key":"4338_CR179","doi-asserted-by":"publisher","first-page":"13461","DOI":"10.2147\/IJN.S498729","volume":"19","author":"X Zhao","year":"2024","unstructured":"Zhao X, Qi X, Liu D, Che X, Wu G. A novel approach for bladder cancer treatment: nanoparticles as a drug delivery system. Int J Nanomed. 2024;19:13461\u201383. https:\/\/doi.org\/10.2147\/IJN.S498729.","journal-title":"Int J Nanomed"},{"key":"4338_CR180","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/pharmaceutics15010211","volume":"15","author":"C Yu","year":"2023","unstructured":"Yu C, Wang S, Lai W-F, Zhang D. The progress of chitosan-based nanoparticles for intravesical bladder cancer treatment. Pharmaceutics. 2023;15:211. https:\/\/doi.org\/10.3390\/pharmaceutics15010211.","journal-title":"Pharmaceutics"},{"key":"4338_CR181","doi-asserted-by":"publisher","first-page":"17704","DOI":"10.1038\/s41598-024-66010-3","volume":"14","author":"C Kong","year":"2024","unstructured":"Kong C, Sun J, Hu X, Li G, Wu S. A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer. Sci Rep. 2024;14:17704. https:\/\/doi.org\/10.1038\/s41598-024-66010-3.","journal-title":"Sci Rep"},{"key":"4338_CR182","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41419-023-06073-8","volume":"14","author":"X Wu","year":"2023","unstructured":"Wu X, Xu L, Li X, Zhou Y, Han X, Zhang W, et al. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway. Cell Death Dis. 2023;14:550. https:\/\/doi.org\/10.1038\/s41419-023-06073-8.","journal-title":"Cell Death Dis"},{"key":"4338_CR183","doi-asserted-by":"publisher","first-page":"e2308762","DOI":"10.1002\/adma.202308762","volume":"36","author":"W Wang","year":"2024","unstructured":"Wang W, Yang F, Zhang L, Wang M, Yin L, Dong X, et al. Targeting DNA damage and repair machinery via delivering WEE1 inhibitor and platinum (IV) prodrugs to stimulate STING pathway for maximizing chemo-immunotherapy in bladder cancer. Adv Mater (Deerf Beach Fla). 2024;36:e2308762. https:\/\/doi.org\/10.1002\/adma.202308762.","journal-title":"Adv Mater (Deerf Beach Fla)"},{"key":"4338_CR184","doi-asserted-by":"publisher","first-page":"2502750","DOI":"10.1002\/advs.202502750","volume":"12","author":"L Peng","year":"2025","unstructured":"Peng L, Zhao A, Li R, Liu Y, Tang D, Deng D, et al. Self-propelled In situ polymerized nanoparticles activating the STING pathway for enhanced bladder cancer immunotherapy. Adv Sci. 2025;12:2502750. https:\/\/doi.org\/10.1002\/advs.202502750.","journal-title":"Adv Sci"},{"key":"4338_CR185","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1038\/s41467-021-26821-8","volume":"12","author":"M Chen","year":"2021","unstructured":"Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, et al. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021;12:6655. https:\/\/doi.org\/10.1038\/s41467-021-26821-8.","journal-title":"Nat Commun"},{"key":"4338_CR186","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.actbio.2023.01.023","volume":"159","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yi C, Zhang L, Zhu X, He Y, Lu H, et al. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for cold tumor immunotherapy. Acta Biomater. 2023;159:338\u201352. https:\/\/doi.org\/10.1016\/j.actbio.2023.01.023.","journal-title":"Acta Biomater"},{"key":"4338_CR187","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41565-021-00962-9","volume":"16","author":"X Sun","year":"2021","unstructured":"Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, et al. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021;16:1260\u201370. https:\/\/doi.org\/10.1038\/s41565-021-00962-9.","journal-title":"Nat Nanotechnol"},{"key":"4338_CR188","doi-asserted-by":"publisher","first-page":"122145","DOI":"10.1016\/j.biomaterials.2023.122145","volume":"299","author":"X Xue","year":"2023","unstructured":"Xue X, Qu H, Bo R, Zhang D, Zhu Z, Xiang B, et al. A transformable nanoplatform with multiple therapeutic and immunostimulatory properties for treatment of advanced cancers. Biomaterials. 2023;299:122145. https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122145.","journal-title":"Biomaterials"},{"key":"4338_CR189","doi-asserted-by":"publisher","first-page":"115265","DOI":"10.1016\/j.colsurfb.2025.115265","volume":"258","author":"Y Wu","year":"2026","unstructured":"Wu Y, Gu X, Li Y, Jiang F, Han J. Light-triggered nanozyme system amplifies oxidative stress for precision cancer therapy. Colloids Surf B Biointerfaces. 2026;258:115265. https:\/\/doi.org\/10.1016\/j.colsurfb.2025.115265.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4338_CR190","doi-asserted-by":"publisher","first-page":"135608","DOI":"10.1016\/j.ijbiomac.2024.135608","volume":"280","author":"AE-Y Chuang","year":"2024","unstructured":"Chuang AE-Y, Tao Y-K, Dong S-W, Nguyen HT, Liu C-H. Polypyrrole\/iron-glycol chitosan nanozymes mediate M1 macrophages to enhance the X-ray-triggered photodynamic therapy for bladder cancer by promoting antitumor immunity. Int J Biol Macromol. 2024;280:135608. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.135608.","journal-title":"Int J Biol Macromol"},{"key":"4338_CR191","doi-asserted-by":"publisher","first-page":"21239","DOI":"10.1039\/d5nr00374a","volume":"17","author":"AE-Y Chuang","year":"2025","unstructured":"Chuang AE-Y, Tao Y-K, Fan Y-J, Chiu H-J, Rethi L, Liu C-H. Synergistic nanoplatform of M1 macrophage-derived extracellular vesicles and MoS2 for tumor-targeted photoimmunotherapy in bladder cancer. Nanoscale. 2025;17:21239\u201359. https:\/\/doi.org\/10.1039\/d5nr00374a.","journal-title":"Nanoscale"},{"key":"4338_CR192","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12951-025-03511-x","volume":"23","author":"W Deng","year":"2025","unstructured":"Deng W, Chen Y, Bai Y, Shang H, Wu J, Zhong Z, et al. Genetically engineered T cell membrane-camouflaged nanoparticles triggered cuproptosis for synergistic bladder cancer photothermal-immunotherapy. J Nanobiotechnol. 2025;23:425. https:\/\/doi.org\/10.1186\/s12951-025-03511-x.","journal-title":"J Nanobiotechnol"},{"key":"4338_CR193","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12951-022-01575-7","volume":"20","author":"Y-C Chin","year":"2022","unstructured":"Chin Y-C, Yang L-X, Hsu F-T, Hsu C-W, Chang T-W, Chen H-Y, et al. Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation. J Nanobiotechnol. 2022;20:373. https:\/\/doi.org\/10.1186\/s12951-022-01575-7.","journal-title":"J Nanobiotechnol"},{"key":"4338_CR194","doi-asserted-by":"publisher","first-page":"845757","DOI":"10.3389\/fimmu.2022.845757","volume":"13","author":"B Luo","year":"2022","unstructured":"Luo B, Wang L, Gao W, Su Y, Lu Y, Zheng J, et al. Using a gene network of pyroptosis to quantify the responses to immunotherapy and prognosis for neuroblastoma patients. Front Immunol. 2022;13:845757. https:\/\/doi.org\/10.3389\/fimmu.2022.845757.","journal-title":"Front Immunol"},{"key":"4338_CR195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10495-021-01703-y","volume":"27","author":"Y Huang","year":"2022","unstructured":"Huang Y, Wang J-W, Huang J, Tang L, Xu Y-H, Sun H, et al. Pyroptosis, a target for cancer treatment? Apoptosis. Int J Program Cell Death. 2022;27:1\u201313. https:\/\/doi.org\/10.1007\/s10495-021-01703-y.","journal-title":"Int J Program Cell Death"},{"key":"4338_CR196","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.7150\/thno.99040","volume":"14","author":"J Tian","year":"2024","unstructured":"Tian J, Gao M, Zhu J, Xu H, Ji H, Xia D, et al. Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis. Theranostics. 2024;14:6692\u2013707. https:\/\/doi.org\/10.7150\/thno.99040.","journal-title":"Theranostics"},{"key":"4338_CR197","doi-asserted-by":"publisher","first-page":"9125","DOI":"10.1021\/acsami.4c20545","volume":"17","author":"C Yang","year":"2025","unstructured":"Yang C, Wang W, Gao Y, Yin L, Pan K, Chen D, et al. Sonodynamic therapy by reactive oxygen species generation-responsive pseudo-semiconducting polymer nanoparticles combined with a fibroblast growth factor receptor inhibitor for enhancing immunotherapy in bladder cancer. ACS Appl Mater Interfaces. 2025;17:9125\u201339. https:\/\/doi.org\/10.1021\/acsami.4c20545.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4338_CR198","doi-asserted-by":"publisher","first-page":"123178","DOI":"10.1016\/j.biomaterials.2025.123178","volume":"319","author":"K Wang","year":"2025","unstructured":"Wang K, Li L, Liang G, Xiao H, Zhang L, Liu T. Sonodynamic activated nanoparticles with Glut1 inhibitor and cystine-containing polymer stimulate disulfidptosis for improved immunotherapy in bladder cancer. Biomaterials. 2025;319:123178. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123178.","journal-title":"Biomaterials"},{"key":"4338_CR199","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/imm.13534","volume":"167","author":"X Wu","year":"2022","unstructured":"Wu X, Wei Y, Lin R, Chen P, Hong Z, Zeng R, et al. Multi-responsive mesoporous polydopamine composite nanorods cooperate with nano-enzyme and photosensitiser for intensive immunotherapy of bladder cancer. Immunology. 2022;167:247\u201362. https:\/\/doi.org\/10.1111\/imm.13534.","journal-title":"Immunology"},{"key":"4338_CR200","doi-asserted-by":"publisher","first-page":"e2212267","DOI":"10.1002\/adma.202212267","volume":"35","author":"B Guo","year":"2023","unstructured":"Guo B, Yang F, Zhang L, Zhao Q, Wang W, Yin L, et al. Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with \u03b1PD-L1 for enhanced cancer immunotherapy. Adv Mater (Deerf Beach Fla). 2023;35:e2212267. https:\/\/doi.org\/10.1002\/adma.202212267.","journal-title":"Adv Mater (Deerf Beach Fla)"},{"key":"4338_CR201","doi-asserted-by":"publisher","first-page":"54453","DOI":"10.1021\/acsami.5c10407","volume":"17","author":"T-Y Cheng","year":"2025","unstructured":"Cheng T-Y, Chang L-C, Yang L-X, Wu S-S, Chin Y-C, Chen Y-J, et al. Bioactive light-responsive Au nanohybrids for reactive oxygen species-driven macrophage reprogramming. ACS Appl Mater Interfaces. 2025;17:54453\u201365. https:\/\/doi.org\/10.1021\/acsami.5c10407.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4338_CR202","doi-asserted-by":"publisher","first-page":"e202417871","DOI":"10.1002\/anie.202417871","volume":"64","author":"J Dai","year":"2025","unstructured":"Dai J, Fang L, Wang X, Hua J, Tu Y, Li S, et al. Configuration-mediated efficient non-radiative transition for R848-assisted photothermal immunotherapy to inhibit tumor growth and metastasis by an In situ tumor vaccine strategy. Angew Chem (Int Ed Engl). 2025;64:e202417871. https:\/\/doi.org\/10.1002\/anie.202417871.","journal-title":"Angew Chem (Int Ed Engl)"},{"key":"4338_CR203","doi-asserted-by":"publisher","first-page":"123677","DOI":"10.1016\/j.biomaterials.2025.123677","volume":"326","author":"R Geng","year":"2026","unstructured":"Geng R, Shang H, Chen Z, Tang K, Liu Y, Zhu J. ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer. Biomaterials. 2026;326:123677. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123677.","journal-title":"Biomaterials"},{"key":"4338_CR204","doi-asserted-by":"publisher","first-page":"19599","DOI":"10.1021\/acsnano.4c17444","volume":"19","author":"H Shang","year":"2025","unstructured":"Shang H, Xia D, Geng R, Wu J, Deng W, Tong Y, et al. Thermosensitive resiquimod-loaded lipid nanoparticles promote the polarization of tumor-associated macrophages to enhance bladder cancer immunotherapy. ACS Nano. 2025;19:19599\u2013621. https:\/\/doi.org\/10.1021\/acsnano.4c17444.","journal-title":"ACS Nano"},{"key":"4338_CR205","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017;14:244\u201355. https:\/\/doi.org\/10.1038\/nrurol.2017.16.","journal-title":"Nat Rev Urol"},{"key":"4338_CR206","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"SM Di Stasi","year":"2006","unstructured":"Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7:43\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(05)70472-1.","journal-title":"Lancet Oncol"},{"key":"4338_CR207","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","volume":"12","author":"SM Di Stasi","year":"2011","unstructured":"Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011;12:871\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(11)70190-5.","journal-title":"Lancet Oncol"},{"key":"4338_CR208","doi-asserted-by":"publisher","first-page":"e2310735","DOI":"10.1002\/adma.202310735","volume":"36","author":"K Liu","year":"2024","unstructured":"Liu K, Wang L, Peng J, Lyu Y, Li Y, Duan D, et al. Drug-Loaded Bacillus Calmette-Gu\u00e9rin Bacteria for Immuno-Chemo Combo Therapy in Bladder Cancer. Adv Mater (Deerf Beach Fla). 2024;36:e2310735. https:\/\/doi.org\/10.1002\/adma.202310735.","journal-title":"Adv Mater (Deerf Beach Fla)"},{"key":"4338_CR209","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.0c01572","author":"SSJMJS Dh","year":"2021","unstructured":"Dh SSJMJS. Immunostimulatory response of RWFV peptide-targeted lipid nanoparticles on bladder tumor associated cells. ACS Appl Bio Mater [Internet] ACS Appl Bio Mater. 2021. https:\/\/doi.org\/10.1021\/acsabm.0c01572. [cited 2025 Dec 8];4.","journal-title":"ACS Appl Bio Mater [Internet] ACS Appl Bio Mater"},{"key":"4338_CR210","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.biomaterials.2018.06.029","volume":"178","author":"G Jia","year":"2018","unstructured":"Jia G, Han Y, An Y, Ding Y, He C, Wang X, et al. NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. Biomaterials. 2018;178:302\u201316. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.06.029.","journal-title":"Biomaterials"},{"key":"4338_CR211","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","volume":"16","author":"S Gavas","year":"2021","unstructured":"Gavas S, Quazi S, Karpi\u0144ski TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett. 2021;16:173. https:\/\/doi.org\/10.1186\/s11671-021-03628-6.","journal-title":"Nanoscale Res Lett"},{"key":"4338_CR212","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PPA.S38578","volume":"7","author":"NL Bragazzi","year":"2013","unstructured":"Bragazzi NL. From P0 to P6 medicine, a model of highly participatory, narrative, interactive, and augmented medicine: some considerations on salvatore iaconesi\u2019s clinical story. Patient Prefer Adherence. 2013;7:353\u20139. https:\/\/doi.org\/10.2147\/PPA.S38578.","journal-title":"Patient Prefer Adherence"},{"key":"4338_CR213","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrclinonc.2010.227","volume":"8","author":"L Hood","year":"2011","unstructured":"Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8:184\u20137. https:\/\/doi.org\/10.1038\/nrclinonc.2010.227.","journal-title":"Nat Rev Clin Oncol"},{"key":"4338_CR214","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s12885-020-07058-y","volume":"20","author":"MJ Bou-Dargham","year":"2020","unstructured":"Bou-Dargham MJ, Sha L, Sang Q-XA, Zhang J. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. BMC Cancer. 2020;20:572. https:\/\/doi.org\/10.1186\/s12885-020-07058-y.","journal-title":"BMC Cancer"},{"key":"4338_CR215","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.3390\/ijms22063036","volume":"22","author":"L Filippi","year":"2021","unstructured":"Filippi L, Frantellizzi V, Chiaravalloti A, Pontico M, De Feo MS, Corica F, et al. Prognostic and theranostic applications of positron emission tomography for a personalized approach to metastatic castration-resistant prostate cancer. Int J Mol Sci. 2021;22:3036. https:\/\/doi.org\/10.3390\/ijms22063036.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04338-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:02:07Z","timestamp":1779717727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04338-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":215,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4338"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04338-w","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review does not report any new studies involving human participants or animals. All studies discussed herein were previously published and were conducted in accordance with relevant institutional and national ethical standards, as well as the Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Weibo Cai declares conflict of interest with the following corporations: Portrai, Inc., rTR Technovation Corporation, Four Health Global Pharmaceuticals Inc., and POP Biotechnologies, Inc. All other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"484"}}